Related Experiment Video
Updated: Feb 7, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Different Diseases, Different Escapes: Trastuzumab Deruxtecan Resistance in HER2-Amplified versus HER2-Low Breast
Tess A O'Meara1,2,3, Paolo Tarantino1,2,3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract:
In this issue of Cancer Discovery, Chen and colleagues demonstrate that, in preclinical models, HER2 expression level directly affects trastuzumab deruxtecan internalization and cytotoxicity, with clinical data revealing divergent target dynamics depending on whether HER2 functions as an oncogenic driver or a dispensable antigen. Together with prior preclinical and clinical evidence, these findings support a context-dependent model in which target downregulation predominates in HER2-low disease, whereas payload resistance or rare binding-site mutations may dominate resistance in HER2-addicted tumors, with important implications for antibody-drug conjugate selection and sequencing. See related article by Chen et al., p. 235.
Insights
HER2 expression levels influence how well trastuzumab deruxtecan works. This antibody-drug conjugate
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- HER2 (Human Epidermal growth factor Receptor 2) is a key protein in some cancers.
- Trastuzumab deruxtecan is an antibody-drug conjugate targeting HER2-expressing tumors.
Purpose of the Study:
- To investigate the relationship between HER2 expression levels and the efficacy of trastuzumab deruxtecan.
- To explore the mechanisms of resistance to trastuzumab deruxtecan in different HER2 contexts.
Main Methods:
- Preclinical models (cell lines and animal models) were used to study HER2 internalization and cytotoxicity.
- Clinical data analysis was performed to assess target dynamics in patients with varying HER2 expression.
Main Results:
- HER2 expression level directly correlated with trastuzumab deruxtecan internalization and cancer cell killing in preclinical models.
- Clinical data showed distinct HER2 target dynamics in HER2-low versus HER2-addicted tumors.
- Mechanisms of resistance varied, including target downregulation in HER2-low disease and payload resistance or mutations in HER2-addicted tumors.
Conclusions:
- A context-dependent model for HER2-targeted therapy is proposed.
- Understanding HER2 dynamics is crucial for optimizing antibody-drug conjugate selection and treatment sequencing.
- Findings have significant implications for personalized cancer treatment strategies.
More Related Videos
10:21Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
Published on: December 25, 2017
06:02Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Related Concept Videos
Treatment Resistant Cancers
Escape Velocity
To calculate the escape velocity, it is assumed that no energy is lost to any frictional forces. In practice, a satellite...
Operational Amplifiers
MOSFET Amplifiers
BJT Amplifiers
In BJT amplifier configurations, particularly in common-emitter setups, the transistor's role...
Instrumentation Amplifier
To overcome this challenge, an ECG machine utilizes an instrumentation amplifier. This specialized amplifier is...